Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results

期刊论文
出版模式：

开放获取
发表日期：

2024年6月13日

查看全文

Andreas R. Gantenbein,
Christophe Bonvin,
Christian P. Kamm,
Christoph J. Schankin,
Chiara Zecca,
Dominik Zieglgänsberger,
Gabriele Susanne Merki-Feld,
Heiko Pohl,
Nicole Rudolph,
Philippe Ryvlin,
Reto Agosti,
Elisabeth Schäfer,
Ina Meyer,
Monika Kulartz-Schank,
Michael E. Arzt

摘要

Background

There are limited real-world data in Switzerland examining the impact of erenumab, a fully human IgG2 monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, on migraine-related quality of life.

Objective

This 18-month interim analysis of 172 patients with episodic or chronic migraine from the SQUARE study provides first prospective insights on the impact of mandatory erenumab treatment interruption, following Swiss-reimbursement requirements, in a real-world clinical setting in Switzerland.

Findings

Recruited patients receiving 70 or 140 mg erenumab underwent treatment interruption on average 11.2 months after therapy onset with a mean duration of 4 months. There were sustained improvements in mean monthly migraine days (MMD) and migraine disability (mMIDAS) during initial treatment with erenumab. Treatment interruption was associated with a temporary worsening of condition. Symptoms ameliorated upon therapy reuptake reaching improvements similar to pre-break within 3 months.

Conclusions

Treatment interruption was associated with a temporary worsening of condition, which improved again after therapy restart.